152 related articles for article (PubMed ID: 35712787)
21. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
22. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
Long Q; Johnson BA; Osunkoya AO; Lai YH; Zhou W; Abramovitz M; Xia M; Bouzyk MB; Nam RK; Sugar L; Stanimirovic A; Williams DJ; Leyland-Jones BR; Seth AK; Petros JA; Moreno CS
Am J Pathol; 2011 Jul; 179(1):46-54. PubMed ID: 21703393
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.
Kondo E; Akatsuka Y; Kuzushima K; Tsujimura K; Asakura S; Tajima K; Kagami Y; Kodera Y; Tanimoto M; Morishima Y; Takahashi T
Blood; 2004 Jan; 103(2):630-8. PubMed ID: 12947002
[TBL] [Abstract][Full Text] [Related]
25. Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection.
Retière C; Lesimple B; Lepelletier D; Bignon JD; Hallet MM; Imbert-Marcille BM
Transplantation; 2003 Jan; 75(1):161-5. PubMed ID: 12544891
[TBL] [Abstract][Full Text] [Related]
26. Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer.
Lin VC; Huang SP; Huang CY; Yu CC; Yin HL; Huang TY; Lee CH; Lu TL; Bao BY
Int J Med Sci; 2017; 14(12):1301-1306. PubMed ID: 29104488
[No Abstract] [Full Text] [Related]
27. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
28. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
Hirata H; Hinoda Y; Kikuno N; Suehiro Y; Shahryari V; Ahmad AE; Tabatabai ZL; Igawa M; Dahiya R
J Urol; 2009 Apr; 181(4):1907-12. PubMed ID: 19237173
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy.
Yu CC; Lin VC; Huang CY; Liu CC; Wang JS; Wu TT; Pu YS; Huang CH; Huang CN; Huang SP; Bao BY
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S492-9. PubMed ID: 23354566
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
31. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.
Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL
J Natl Cancer Inst; 2006 Oct; 98(19):1420-4. PubMed ID: 17018789
[TBL] [Abstract][Full Text] [Related]
32. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
[TBL] [Abstract][Full Text] [Related]
33. Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Corradi JP; Cumarasamy CW; Staff I; Tortora J; Salner A; McLaughlin T; Wagner J
Prostate; 2021 Jul; 81(10):694-702. PubMed ID: 34002865
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy.
Tanaka T; Kawashima A; Rangel LJ; Schulte PJ; Froemming AT; King BF; Mynderse LA; Karnes RJ
J Urol; 2022 May; 207(5):1038-1047. PubMed ID: 34981952
[TBL] [Abstract][Full Text] [Related]
35. T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantation.
Toya T; Taguchi A; Kitaura K; Misumi F; Nakajima Y; Otsuka Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Yamada Y; Marumo A; Noguchi Y; Yoshifuji K; Mukae J; Inamoto K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Ohashi K; Suzuki R; Nagamatsu T; Doki N
Sci Rep; 2020 Dec; 10(1):22218. PubMed ID: 33335252
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
37. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
38. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
Huang SP; Huang CY; Wu WJ; Pu YS; Chen J; Chen YY; Yu CC; Wu TT; Wang JS; Lee YH; Huang JK; Huang CH; Wu MT
Int J Cancer; 2006 Oct; 119(8):1902-7. PubMed ID: 16708371
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
40. Recurrence rate of localized prostate cancer after radical prostatectomy according to D'amico risk classification in a tertiary referral hospital: association study.
Valdez-Vargas AD; Sánchez-López HM; Badillo-Santoyo MA; Maldonado-Valadez RE; Manzo-Pérez BO; Pérez-Abarca VM; Manzo-Pérez G; Vanzzini-Guerrero MA; Álvarez-Canales JA
Cir Cir; 2021; 89(4):520-527. PubMed ID: 34352860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
